GlassScriptPhysician profile
Joseph M Dulac
NPI 1760421234
$3,830.75
in general payments reported to CMS, 2019-2025
27 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $519 · 2021: $612 · 2022: $270 · 2023: $732 · 2024: $590 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.38 | 2020-2025 | Vraylar |
| Glaxosmithkline, LLC. | $438.26 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $379.99 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.82 | 2019-2024 | Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $313.08 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $307.59 | 2019-2024 | Wegovy, Saxenda, Rybelsus |
| Lilly USA, LLC | $303.67 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $137.43 | 2019-2023 | Myrbetriq |
| Exact Sciences Corporation | $129.00 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $118.49 | 2019 | |
| Lundbeck LLC | $111.52 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $107.32 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $106.36 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.61 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $71.11 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.21 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $41.82 | 2021 | |
| Abbott Laboratories | $37.64 | 2019 | |
| Gilead Sciences, INC. | $31.32 | 2020 | |
| Hologic Sales and Service, LLC | $22.39 | 2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $22.27 | 2024 | |
| Idorsia Pharmaceuticals US INC | $21.96 | 2023 | Quviviq |
| Shire North American Group INC | $20.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.26 | 2023 | Eliquis |
| Amarin Pharma, INC. | $16.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.73 | 2025 | Caplyta |
| Verona Pharma, INC. | $15.69 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dulac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.